SCHEMBL21296974

SCHEMBL21296974

C=Cc1cccc(Oc2[nH]nnc2C(=O)OCC)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.42
GABRA1 P14867 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
GABRA2 P47869 1/20 0.41
MCL1 Q07820 1/20 0.39
KDM4E B2RXH2 4/20 0.38
HPGDS O60760 1/20 0.37
POLB P06746 1/20 0.37
F2 P00734 1/20 0.36
F10 P00742 1/20 0.36
ALDH1A1 P00352 6/20 0.35
LMNA P02545 4/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
ALOX12 P18054 2/20 0.35
HTT P42858 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29799138 0.90 MAPT (0.43) MAPTKDM4EHPGDSPOLBF2
SCHEMBL21296861 0.90 MAPT (0.43) MAPTKDM4EHPGDSPOLBF2
SCHEMBL21296885 0.83 HAO1 (0.39) HAO1
SCHEMBL29799051 0.83 HAO1 (0.39) HAO1
SCHEMBL23001771 0.83 F10 (0.41) MAPTGABRA1GABRG2GABRB3GABRA5
SCHEMBL21296880 0.83 ELANE (0.44) MAPTKDM4EHPGDSPOLBF2
SCHEMBL29891533 0.83 F10 (0.41) MAPTGABRA1GABRG2GABRB3GABRA5
SCHEMBL29692449 0.83 ELANE (0.44) MAPTKDM4EHPGDSPOLBF2
SCHEMBL22795534 0.82 HPGDS (0.48) MAPTKDM4EHPGDSPOLBALDH1A1
SCHEMBL21296986 0.80 HAO1 (0.53) GABRA1GABRG2GABRB3GABRA5GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX MAPT 1559/4885GABRA1 3606/4885GABRG2 2918/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX MAPT 1559/4885GABRA1 3606/4885GABRG2 2918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.